Bevacizumab was the first anti-VEGF monoclonal antibody (MAB) approved for the treatment of metastatic ColoRectal cancer (mCRC), in combination with chemotherapy [10,15], which led to an increased overall survival in patients with mCRC [16]. Here, VEGFA is linked to metastatic colorectal cancer.